Adeno-associated viruses (AAVs) are single-stranded DNA viruses that are endemic in human populations without known clinical sequelae and are being evaluated as vectors for human gene therapy. To better understand the biology of this virus, we examined a number of nonhuman primate species for the presence of previously uncharacterized AAVs and characterized their structure and distribution. AAV genomes were widely disseminated throughout multiple tissues of a variety of nonhuman primate species. Surprising diversity of sequence, primarily localized to hypervariable regions of the capsid protein, was detected. This diversity of sequence is caused, in part, by homologous recombination of co-infecting parental viruses that modify the serologic reactivity and tropism of the virus. This is an example of rapid molecular evolution of a DNA virus in a way that was formerly thought to be restricted to RNA viruses.A deno-associated viruses (AAVs) belong to the Parvoviridae family, which is characterized as small animal viruses with linear single-stranded DNA genomes that replicate in the presence of helper virus such as adenovirus (1). AAVs are being evaluated as vectors for human gene therapy (2). The initial characterization of this group of viruses was based on serologic crossreactivity by using complement fixation and neutralizing assays (3). Six distinct serotypes of AAV have been described, of which five were initially isolated as contaminants of adenovirus preparations (4-6). Sequence analysis of selected AAV isolates revealed divergence throughout the genome that is most concentrated in hypervariable regions (HVRs) of the capsid proteins (7-10). Epidemiological data indicate that all known serotypes are endemic to primates, although isolation of clinical isolates has been restricted to AAV2 and AAV3 from anal and throat swabs of human infants and AAV5 from a human condylomatous wart (11)(12)(13)(14). No known clinical sequelae have been associated with AAV infection. Vectors based on replication-defective forms of AAV have been evaluated in preclinical and clinical models of gene therapy (2). Detection and Recovery of AAV Sequences. DNA was extracted and analyzed for the presence of AAV DNA by using a PCR strategy to amplify a 255-bp (15) fragment called the ''signature region'' by using conserved oligonucleotides. To directly amplify a 3.1-kb full-length Cap fragment from NHP tissue and blood DNAs, two other highly conserved regions were identified in AAV genomes for use in PCR amplification of large fragments. A primer within a conserved region located in the middle of the Rep gene was selected (AV1ns, 5Ј-GCTGCGTCA ACTGGACCA AT-GAGAAC-3Ј) in combination with the 3Ј primer located in another conserved region downstream of the Cap gene (AV2cas, 5Ј-CGCAGAGACCAAAGTTCAACTGAAACGA-3Ј) for amplification of full-length cap fragments. The PCR products were Topo-cloned (Invitrogen), and sequence analysis was performed by Qiagengenomics (Qiagengenomics, Seattle) with an accuracy of Ն99.9%. A total of 50 capsid clones were i...

Cell lines stably expressing rep/cap are important tools for studying adeno-associated virus (AAV) biology and producing AAV vectors. Several rep/cap cell lines have been isolated, each of which is based on HeLa cells. Infection of these cell lines with adenovirus for production of AAV vector is associated with substantial amplification of the rep/cap gene. Concerns over the presence of human papilloma viral (HPV) sequences in HeLa cells may limit use of such lines for production of clinical-grade vectors. Here we describe a non-HeLa-derived rep/cap cell line called K209, generated by stable transfection of A549 cells with a plasmid construct containing the P5 rep/cap cassette from AAV2. Infection of K209 cells with adenovirus leads to a 1000-fold amplification of the rep/cap gene with high-yield production of AAV vectors. The multiplicity of infection (MOI) of adenovirus that led to maximum amplification of the rep/cap gene and high-level production of AAV is 10 times higher in the HeLa-based cell line than that required in K209 cells. Our data suggest that papilloma-derived gene products present in HeLa cells are not required for high-yield production of AAV vectors.